Predictive factors for failure of the levonorgestrel releasing intrauterine system in women with heavy menstrual bleeding

被引:4
作者
Beelen, Pleun [1 ,2 ]
van den Brink, Marian J. [3 ]
Herman, Malou C. [4 ]
Geomini, Peggy M. [1 ]
Duijnhoven, Ruben G. [5 ]
Bongers, Marlies Y. [1 ,6 ]
机构
[1] Maxima MC, Dept Obstet & Gynecol, NL-5504 DB Veldhoven, Netherlands
[2] Univ Maastricht, Dept Gen Practice, Maastricht, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice & Elderly Care Med, Groningen, Netherlands
[4] Jeroen Bosch Hosp, Dept Obstet & Gynecol, sHertogenbosch, Netherlands
[5] Acad Med Ctr, Dept Obstet & Gynecol, Amsterdam, Netherlands
[6] Univ Maastricht, Res Sch Grow, Maastricht, Netherlands
关键词
Heavy menstrual bleeding; Levonorgestrel intrauterine system; Failure; Prognosis;
D O I
10.1186/s12905-021-01210-x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundThis study was conducted to identify factors that are associated with failure of treatment using the levonorgestrel releasing intrauterine system (LNG-IUS) in women with heavy menstrual bleeding.MethodsFor this study, data of a cohort of women treated with an LNG-IUS was used. Women who suffered from heavy menstrual bleeding, aged 34 years and older, without intracavitary pathology and without a future child wish, were recruited in hospitals and general practices in the Netherlands. Eight potential prognostic baseline variables (age, body mass index, caesarean section, vaginal delivery, previous treatment, anticoagulant use, dysmenorrhea, and pictorial blood assessment score) were analyzed using univariable and multivariable regression models to estimate the risk of failure. The main outcome measure was discontinuation of the LNG-IUS within 24 months of follow up, defined as removal of the LNG-IUS or receiving an additional intervention.ResultsA total of 209 women received the LNG-IUS, 201 women were included in the analyses. 93 women (46%) discontinued LNG-IUS treatment within 24 months. Multivariable analysis showed younger age (age below 45) (adjusted RR 1.51, 95% CI 1.10-2.09, p=.012) and severe dysmenorrhea (adjusted RR 1.36, 95% CI 1.01-1.82, p=.041) to be associated with a higher risk of discontinuation.ConclusionsHigh discontinuation rates are found in women who receive an LNG-IUS to treat heavy menstrual bleeding. A younger age and severe dysmenorrhea are found to be risk factors for discontinuation of LNG-IUS treatment. These results are relevant for counselling women with heavy menstrual bleeding.
引用
收藏
页数:7
相关论文
共 50 条
[41]   Endometrial ablation plus levonorgestrel releasing intrauterine system versus endometrial ablation alone in women with heavy menstrual bleeding: study protocol of a multicentre randomised controlled trial; MIRA2 trial [J].
Tamara J. Oderkerk ;
Pleun Beelen ;
Peggy M. A. J. Geomini ;
Malou C. Herman ;
Jaklien C. Leemans ;
Ruben G. Duijnhoven ;
Judith E. Bosmans ;
Justine N. Pannekoek ;
Thomas J. Clark ;
Ben Willem J. Mol ;
Marlies Y. Bongers .
BMC Women's Health, 22
[42]   Heavy menstrual bleeding in women with inherited bleeding disorders [J].
Djambas Khayat, Claudia ;
Gouider, Emna ;
von Mackensen, Sylvia ;
Abdul Kadir, Rezan .
HAEMOPHILIA, 2020, 26 :16-19
[43]   Impact of a new levonorgestrel intrauterine system, Levosert®, on heavy menstrual bleeding: results of a one-year randomised controlled trial [J].
Mawet, Marie ;
Nollevaux, Fabrice ;
Nizet, Dominique ;
Wijzen, Fabienne ;
Gordenne, Valerie ;
Tasev, Niso ;
Segedi, Dimitrije ;
Marinescu, Bogdan ;
Enache, Andreea ;
Parhomenko, Vadim ;
Frankenne, Francis ;
Foidart, Jean-Michel .
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2014, 19 (03) :169-179
[44]   Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis [J].
Kelekci, Sefa ;
Kelekci, Kiymet Handan ;
Yilmaz, Bulent .
CONTRACEPTION, 2012, 86 (05) :458-463
[45]   Clinical efficacy of levonorgestrel releasing intrauterine system for the treatment of adenomyosis in perimenopausal women [J].
Ma, Ju-Qi ;
Guo, Chun-Fen ;
Hasim, Ayshamgul .
CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2018, 45 (03) :387-390
[46]   The levonorgestrel intrauterine system: the benefits of reduced bleeding [J].
Cameron, IT .
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2001, 6 :27-32
[47]   Factors Predicting Removals of the Levonorgestrel-Releasing Intrauterine System in an Adolescent Cohort [J].
Baum, Alexandra ;
Chan, Kiri ;
Sachedina, Aalia ;
Grover, Sonia R. .
JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY, 2024, 37 (02) :171-176
[48]   Quality of Life of Japanese Dysmenorrhea/Heavy Menstrual Bleeding Patients Treated with Levonorgestrel Intrauterine Delivery System in a Real-World Setting [J].
Momoeda, Mikio ;
Akira, Shigeo ;
Harada, Tasuku ;
Kitawaki, Jo ;
Maeda, Nagamasa ;
Ota, Ikuko ;
Yoshihara, Keisuke ;
Takahashi, Noriko .
ADVANCES IN THERAPY, 2022, 39 (08) :3616-3634
[49]   Quality of Life of Japanese Dysmenorrhea/Heavy Menstrual Bleeding Patients Treated with Levonorgestrel Intrauterine Delivery System in a Real-World Setting [J].
Mikio Momoeda ;
Shigeo Akira ;
Tasuku Harada ;
Jo Kitawaki ;
Nagamasa Maeda ;
Ikuko Ota ;
Keisuke Yoshihara ;
Noriko Takahashi .
Advances in Therapy, 2022, 39 :3616-3634
[50]   Consecutive Use of the 52 mg Levonorgestrel-releasing Intrauterine System: Variations in Bleeding Patterns [J].
Wittmann, Barbara Zantut ;
Monteiro, Ilza ;
Juliato, Cassia ;
Fernandes, Arlete .
REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2020, 42 (04) :194-199